Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Update

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) was the recipient of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 1,670,000 shares, a decrease of 19.7% from the February 28th total of 2,080,000 shares. Approximately 14.1% of the company's shares are sold short. Based on an average trading volume of 526,700 shares, the short-interest ratio is presently 3.2 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets grew its stake in shares of Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock valued at $47,000 after buying an additional 1,698 shares during the last quarter. MetLife Investment Management LLC boosted its stake in shares of Jasper Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company's stock valued at $129,000 after purchasing an additional 3,873 shares during the period. Wells Fargo & Company MN increased its stake in Jasper Therapeutics by 106.7% in the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after buying an additional 3,828 shares during the period. EntryPoint Capital LLC purchased a new stake in Jasper Therapeutics in the 4th quarter valued at about $223,000. Finally, Tema Etfs LLC bought a new position in Jasper Therapeutics in the 4th quarter worth about $266,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on JSPR shares. Royal Bank of Canada lowered their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a report on Thursday, January 9th. JMP Securities restated a "market outperform" rating and set a $70.00 target price on shares of Jasper Therapeutics in a report on Monday, January 6th. BMO Capital Markets started coverage on Jasper Therapeutics in a research report on Friday, December 6th. They issued an "outperform" rating and a $63.00 price target on the stock. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. Finally, UBS Group initiated coverage on Jasper Therapeutics in a report on Thursday, February 13th. They set a "buy" rating and a $38.00 price target on the stock. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Jasper Therapeutics currently has an average rating of "Buy" and a consensus price target of $62.50.

Remove Ads

Jasper Therapeutics Stock Down 6.5 %

NASDAQ JSPR traded down $0.26 during trading hours on Friday, reaching $3.75. The company's stock had a trading volume of 128,387 shares, compared to its average volume of 278,336. The company has a market capitalization of $56.33 million, a price-to-earnings ratio of -0.79 and a beta of 2.23. Jasper Therapeutics has a 1 year low of $3.67 and a 1 year high of $30.70. The firm's 50-day moving average price is $5.56 and its 200-day moving average price is $14.33.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.35). Equities research analysts anticipate that Jasper Therapeutics will post -4.47 EPS for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.